Grant Title: NATIONAL COOPERATIVE DRUG DISCOVERY AND DEVELOPMENT GROUPS (NCDDDG) FOR THE TREATMENT OF MENTAL DISORDERS, DRUG OR ALCOHOL ADDICTION (U01/U19)

Funding Opportunity Number: CFDA Number(s): 93.242, 93.273, 93.279. Funding Opportunity Number: PAR-08-238

Area of Research: Create multidisciplinary research groups or partnerships for the discovery of pharmacological agents to treat and to study mental illness, drug or alcohol addiction.


Application Deadline: Oct 3, 2008; Feb 24, 2009; Sep 17, 2009; Feb 24, 2010; Sep 17, 2010; Feb 24, 2011.

Amount: Up to $500,000. Budgets for direct costs exceeding $500,000 per year require prior approval.

Length of Support: Up to five years.

Eligible Applicants: Public and State controlled institutions of higher education. See full announcement for other eligible applicants.

Agency/Department: Department of Health and Human Services, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Summary: The purpose of the National Cooperative Drug Discovery and Development Group (NCDDDG) Program is to create multidisciplinary research groups or partnerships for the discovery of pharmacological agents to treat and to study mental illness, drug or alcohol addiction. The objectives of this program are to: accelerate innovative drug discovery; develop pharmacologic tools for basic and clinical research on mental disorders, or drug or alcohol addiction; develop and validate models for evaluating novel therapeutics for mental disorders; and support early phase human clinical testing to rapidly assess the safety and efficacy of promising drug candidates and new indications for IND-ready drugs for the treatment of mental disorders or alcohol addiction. The National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to advance the discovery, preclinical development, and proof of concept testing of new, rationally based candidate medications to treat mental disorders or drug or alcohol addiction, and to develop novel ligands as tools to further characterize existing or to validate new drug targets. Partnerships between academia and industry are strongly encouraged.

Detail Information: http://grants.nih.gov/grants/guide/pa-files/PAR-08-238.html